Studies on anti-cancer and immune enhancing effects of carboxymethyl-ch-itosan

Abstract

Abstract: AIM: To detemine the anti-cancer andimmune-enhancing effects of carboxymethyl-chitosan. METHODS: MTT method was used to detect the activity of carboxymethyl-chitosan in vitro; S180 tumor model wasbuilt to study the antitumor ffeet of carboxymethyl-chi-tosan in tito. Flow cytonetric analysis was employed toanalysis tumor cell eyele and apoptosis. ELISA was usedto measure the immune modulation activity of carboxym-ethyi chitosan. RESULTS: Carboxymethyl-chitosan sup-pressed tumorcells. The IC₅₀ is 30 μg/mL. The cell ey-rle was arested in Gphase afer Carboxynethyi-chitsan treatment, and apoplosis of cancer cell was induced obvi-ously. Carboxymethyl-chitosan also presented proninenteffects on anti-cancer and imanune enhancement. CONCLUSION: Carboxymethyl-chitosan exhibit anti-caner effects significantly by direetly illing cancer celis and in-mune enhancement.

Key words: carboxymethyl-chitosan, tumor, multi-plication restriction, inmunity

CLC Number:

R965.2

YANG Jing-ya, YU You-jun, WU Hong-zhong, LIU Jian-wen. Studies on anti-cancer and immune enhancing effects of carboxymethyl-ch-itosan[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(12): 1390-1394.

References

[1] 何乃苦,宋鹏飞,王荣民.甲壳素/壳聚糖及其衍生物抗菌、抗肿瘤活性研究进展[J].高分子通报,2004:14-18.
[2] Maeda Y, Kimura Y. Antitumor effects of various low-molecµlar-weight chitosaru are due to increased natural killer activity of intestinal intraepithelial nphocytes in coma 180-bearing mice[J]. J Nutr, 2004;134:945-950.
[3] Torzsas TL, Kendall CW, Sugano M, et al. influence of high and low molecµlar weight chitosan on colonic cell proliferation and aberrant crypt foci development in CF! mice[J]. Food Chem Toxicol, 1996;34:73-77.
[4] Pae HO, Seo WG,Kim NY, et al. Induction of differentiation in acutle promyelocytic leukemia cells (HL-60) bywater-soluble chitosan oligomer[J]. Leuk Res, 200l;25: 339-346.
[5] 杜昱光,白雪芳,金宗濂,等.壳寡糖抑制肿瘤作用的研究[J].中国海洋药物,2002;21:18-21.
[6] 赵呈裕,杨英,李虹,等.毛柄金钱菌水溶性多糖抑制小鼠S180实体瘤生长的研究[J].华西医科大学学报,1988;19-20.
[7] 蒋挺大, 壳聚糖[M] 壳聚糖[M].北京:化学工业出版社,2001:1-5.
[8] Muzzarelli RAA. Human enzymatic activities related to the ther-apeutical administration of chitin derivatives[J]. Cell Mol LifeSci, 1997;53:131-140.
[9] Dumitriu S. Polysaccharides, structural diversity and funetionalversatility[M]. New York: Marcel Dekker, 1998;31:223-246.10 Majeti NV, Ravi Kumar. A review of chitin and chitosan appli-cations[J]J. React Functional Polym, 2000;46:1-27.
[10] 张文清,柴平海,夏玮.NaOC/H2O2协同氧化制备壳寡糖[J].华东理工大学学报,200:26:425-428.
[11] 杨靖亚,刘建文,刘承初,等.羧甲基壳聚糖对人高转移肺癌细胞-95D增殖能力和体外转移能力的抑制作用[].中国临床药理学与治疗学,206:1:6-9.
[12] Ueno H, Morl T, Fujinaga T. Chiosan nan oariles: a newvehicle for the improvement of the delivery of drugs to the ocularsurface[J]. Adv Drug Deliv Rev, 2001;52: 105-115.
[13] Cho YW, Cho YN, Chung SH, et al. Water-soluble chitin as a wound healing accelerator[J]. Biomaterials, 1999;20: 2139-2145.

[1]	LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
[2]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[3]	WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi. Research progress of lactate dehydrogenase A in digestive system tumors and related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 445-454.
[4]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[5]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[6]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[7]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[8]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[9]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[10]	GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
[11]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[12]	HONG Ziqiang, GOU Wenxi, CUI Baiqiang, BAI Xiangdou, JIN Dacheng, GOU Yunjiu. Role of the m7G methyltransferase METTL1 in tumours [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 93-100.
[13]	WANG Yali, HUO Xulei, CHEN Feng, LI Shenglan, ZHENG Xiaohong, WANG Can, LI Wenbin. Research progress on the antitumor effect of nifurtimox [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 955-960.
[14]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[15]	MA Wangbo, Ma Yue, FAN Fangtian, ZHANG Yuhan, CHANG Jingwen, ZHOU Zhihua. Effects of Shenqi fuzheng injection on low-glucose-mediated immunosuppressive microenvironment and its mechanism of action [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 136-143.